The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series

Nasikarn Angkasekwinai[1], Suvimol Niyomnaitham[2,3], Jaturong Sewatanon[4], Supaporn Phumiamorn[5], Kasama Sukapirom[6,7], Sansnee Senawong[8], Surakameth Mahasirimongkol[5], Zheng Quan Toh[9], Pinklow Umrod[8], Thitiporn Somporn[5], Supaporn Chumpol[5], Kanokphon Ritthitham[5], Kulkanya Chokephaibulkit[3,10*]

[1]Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[2]Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[3]Siriraj Institute of Clinical Research (SICRES), Mahidol University, Thailand

[4]Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[5]Department of Medical Sciences, Ministry of Public Health, Thailand

[6]Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[7]Siriraj Center of Research Excellence in Microparticle and Exosome in Disease, Thailand

[8]Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[9]Murdoch Children's Research Institute, Parkville, VIC 3052, Australia

[10]Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Corresponding author:

Kulkanya Chokephaibulkit, MD

Professor of Pediatrics,

Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University

Siriraj Institute of Clinical Research (SICRES)

2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand

Tel: (+66) 2-4141899; Fax: (+66) 2-4128243

E-mail: kulkanya.cho@mahidol.ac.th

Nasikarn Angkasekwinai and Suvimol Niyomnaitham equally contributed to the research work.

Abstract word count: 149

Manuscript Text word count: 3569

Abstract

The appropriate COVID-19 booster vaccine following inactivated or adenoviral vector COVID-19 vaccination is unclear. We evaluated the safety and immunogenicity of different booster vaccines, inactivated (BBIBP-CorV), chimpanzee adenoviral vector (ChAdOx1), or mRNA (BNT162b2 at full (30 µg), or half (15 µg) dose) in healthy adults who received 2-dose primary series of either inactivated vaccine (CoronaVac) or ChAdOx1 8-12 weeks earlier. Overall, the adverse events for all booster vaccines were mild and moderate. Two weeks post-booster dose, the neutralising antibody titres against Delta variant in CoronaVac-prime and ChAdOx1-prime were highest with for 30µg-BNT162b2 (411 vs 470) and 15µg-BNT162b2 (499 vs 358); followed by ChAdOx1 (271 vs 69), and BBIBP-CorV (61.3 vs 49). BNT162b2 also induced higher interferon gamma response. Heterologous COVID-19 boosting vaccination with BNT162b2 is the most immunogenic following CoronaVac or ChAdOx1 primary series. A lower dose BNT162b2 may be used as booster in settings with limited vaccine supply.

Introduction

Both CoronaVac (an inactivated whole-virion SARS-CoV-2 vaccine, Sinovac Life Science) and ChAdOx1 (a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein, Oxford, AstraZeneca) are safe and effective against symptomatic COVID-19 caused by the ancestral Wuhan strain, and to a lower extent against the delta variant[1-7]. These two vaccines are among the most widely used vaccines in low- and middle-income countries and some high-income countries.

There are increasing reports of breakthrough infections following COVID-19 vaccination, which is likely due to a combination of waning immunity and the emergence of SARS-CoV-2 variants, particularly the delta variant[8-11]. While the antibody threshold of protection has not been identified, higher antibody levels are likely to be associated with greater protection, including the variants[7]. Furthermore, cell mediated immune responses (CMIR) generated following vaccination are also likely to play an important role in protection.

Several studies have demonstrated improved humoral responses with heterologous COVID-19 prime-boost vaccination, primarily on ChAdOx1 and mRNA vaccines[12-16]. However, other combinations of prime-boost COVID-19 vaccination involving inactivated COVID-19 vaccines have not been evaluated. A recent study of reduced dosage of a booster shot of mRNA-1273 vaccine was found to be highly immunogenic[17]. It is therefore possible that the dosage required for booster may be less than the primary series, particularly with the highly immunogenic vaccine like mRNA vaccines. Reduced dosage of the vaccine will therefore increase accessibility, reduced cost, and could be an important strategy for public health to control the outbreak.

In this study, we examined the immunogenicity and safety of different booster vaccine platforms and reduced dosages (BBIBP-CorV, inactivated vaccine manufactured by Sinopharm;

ChAdOx1, chimpanzee adenoviral vector vaccine manufactured by AstraZeneca/Oxford; full dose (30 µg) BNT162b2, mRNA vaccine manufactured by Pfizer; and half dose (15 µg) BNT162b2) in healthy adults aged 18-60 years who received a 2-dose primary series of CoronaVac 4 weeks apart (CoronaVac-prime) or ChAdOx1 vaccine 8-10 weeks apart (ChAdOx1-prime).

Results

A total of 352 participants were enrolled (179 and 173 participants in CoronaVac- and ChAdOx1-prime group), 285 (81%) were female, and the median age was 39 (interquartile range, IQR: 31-47) years. The demographic of the study participants receiving different booster vaccine was shown in Table 1.

Adverse events (AEs)

Among CoronaVac-prime group, the frequency of overall AEs was the highest after boosting with ChAdOx1 (98%), followed by 30 µg BNT162b2 (92%), 15 µgBNT162b2 (80%), and BBIBP-CorV (70%); whereas in ChAdOx1-prime group, the highest rate of overall AEs was reported after boosting with 30 µg BNT162b2 (98%), followed by 15 µgBNT162b2 (88%), ChAdOx1 (72%), and BBIBP-CorV (61%) (Fig. 1, Supplementary Table 1). Systemic AEs were in the same trend as local AEs. All AEs were mild (grade 1) or moderate (grade 2) in severity and recovered within 2-3 days. No serious AEs was found in this study.

Anti-SARS-CoV-2 RBD IgG responses

Prior to the booster dose (8-12 weeks post-primary series), 175/179 (97.8%) participants in CoronaVac-prime and all (172/173, 99.4%) in ChAdOx1-prime were seropositive; however, the

anti-RBD IgG geometric mean concentrations (GMCs) were lower in CoronaVac-prime group than ChAdOx1-prime group (36.31 BAU/mL range: 33-38 BAU/mL vs 98.27 BAU/mL, range: 90-116 BAU/mL) (Fig. 2A). For the CoronaVac-prime group, at 2 weeks after the booster vaccination, the anti-RBD IgG GMC in the 30 µg BNT162b2 group (5,152 BAU/mL) was significantly higher than other booster vaccine groups: 15 µg BNT162b2 (3,981 BAU/mL), ChAdOx1 (1,358 BAU/mL), and BBIBP-CorV (154 BAU/mL) (Fig. 2A). A booster dose of BBIBP, ChAdOx1, 30µg BNT162b2 or 15µg BNT162b2 increased anti-RBD IgG GMC by 4.5, 35.6, 154.7, and 105.7 times from baseline, respectively. The geometric mean ratio (GMR, 95% CI) between post-boost and post-primary series of CoronaVac were 0.94 (0.53, 1.67) for BBIBP-CorV, 8.26 (6.29, 10.85) for ChAdOx1, 31.34 (24.37, 40.30) for 30µg BNT162b2, and 24.22 (18.60, 31.54) for 15µg BNT162b2, respectively (Supplementary Table 2).

For the ChAdOx1-prime group, at 2 weeks after the booster dose, the anti-RBG IgG GMC was highest in the participants receiving a booster dose of 30 µg BNT162b2 at the level of 2,364 BAU/mL, followed by 15 µgBNT162b2 (1,962 BAU/mL), ChAdOx1 (246.4 BAU/mL), and BBIBP-CorV (128.1 BAU/mL). However, there was no statistical difference in the anti-RBD IgG GMC between 30 µg and 15 µg BNT162b2 groups (*P*=0.1381) (Fig. 2B). A booster dose of BBIBP, ChAdOx1, 30µg BNT162b2, or 15µg BNT162b2 increased GMCs for 1.2, 2.3, 25.1, and 21.8 times from baseline, respectively. The GMR (95% CI) between post-boost and post-primary series of ChAdOx1 were 0.46 (0.28, 0.65) for BBIBP-CorV, 0.88 (0.58, 1.13) for ChAdOx1, 8.49 (5.71, 10.44) for 30µg BNT162b2, and 7.04 (4.69, 8.84) for 15µg BNT162b2, respectively (Supplementary Table 2). The post-boost GMC levels in ChAdOx1-prime group were generally lower than those in the CoronaVac-prime group for all booster vaccines. (Fig. 2C).

Neutralising antibody response against SARS-CoV-2 variants

The $PRNT_{50}$ GMTs against the Delta variant among CoronaVac-prime participants were highest after a booster dose of 15 µg BNT162b2 (499.1), followed by 30 µg BNT162b2 (411.1), ChAdOx1 (271.2), and BBIBP-CorV (61.3); whereas among ChAdOx1-prime group, the highest $PRNT_{50}$ GMT was after a booster dose of 30 µg BNT162b2 (470), followed by 15 µg BNT162b2 (358.4), ChAdOx1 (69.1), and BBIBP-CorV (49.1) (Fig. 3A). A similar trend was observed for $PRNT_{50}$ GMT against the Beta variant (Fig. 3B). There was no statistical difference of $PRNT_{50}$ GMT between boosting with 30 µg and 15 µg BNT162b2 regardless of the vaccine given as primary series and the type of variants. The $PRNT_{50}$ GMT of the Beta variants were around 1.5-fold lower than the Delta variants for both CoronaVac-prime and ChAdOx1-prime groups (Fig. 3C). The GMRs (95% CI) of $PRNT_{50}$ titres between post-boost and post-primary series were highest among the participants who received BNT162b2 boosting vaccination in both CoronaVac-prime and ChAdOx1-prime groups for both Delta and Beta variants (Table 2). The anti-SARS-CoV-2 RBD IgG levels and the $PRNT_{50}$ titres against Delta variant (Fig. 4A and Fig. 4B) or Beta variant (Fig. 4C and Fig. 4D) were highly correlated (r = 0.49-0.89) particularly in the ChAdOx1-primed group.

Interferon gamma responses (Interferon gamma release assay, IGRA)

At 8-12 weeks following the primary series, 62/173 (35.8%) of participants in ChAdOx1-prime group had positive IGRA, while only 45/179 (25%) CoronaVac-prime group was positive (P=0.029). Among those who were seronegative in both CoronaVac-prime and ChAdOx1-prime group, IGRA conversion was the highest after a booster dose of 30 µg BNT162b2, followed by 15 µg BNT162b2, ChAdOx1, and BBIBP-CorV (Table 1). Interestingly, none of the study

participants who were IGRA-negative at baseline in theChAdOx1-prime group had a positive IGRA response following boosting with BBIBP-CorV or ChAdOx1 (Table 1) (Supplementary Fig. S1).

Discussion

In this study, we found that BBIBP-CorV, ChAdOx1, BNT162b2 (standard and reduced dosage) given as booster dose to individuals who received either CoronaVac or ChAdOx1 primary series were safe and immunogenic. BNT162b2 as a booster vaccine induced the highest humoral and cellular immunity compared to BBIBP-CorV or ChAdOx1. An interesting observation was the higher immune responses in the CoronaVac-primed group compared to the ChAdOx1-prime group when boosting with BNT162b2 at the similar interval after primary series.

Booster vaccinations using BBIBP-CorV, ChAdOx1, BNT162b2 (standard and reduced dosage) was safe and well tolerated, although the overall proportion who reported AEs (61-98%) were high, particularly among BNT162b2 recipients, as well as among ChAdOx1 who received it as the first time among CoronaVac-prime group. All AEs were mild or moderate in severity and no serious AEs was reported. These AEs rates were similar to those reported in COVID-19 vaccine primary series and booster studies[17-18]. The AEs frequencies following ChAdOx1 and BBIBP-CorV in this study were consistent with those reported in the primary series vaccination in this population[7].

Heterologous boosting vaccination in our study were found to be more immunogenic than homologous boosting regimen of ChAdOx1 or homologous vaccine platforms (CoronaVac prime-BBIBP-CorV boost; inactivated vaccines). The higher humoral immune responses following heterologous ChAdOx1 prime-BNT162b2 boost vaccination compared to homologous ChAdOx1

prime-ChAdOx1 boost vaccination observed in our study was consistent with what was reported in a cohort study[19]. However, no clinical studies have yet to report on the heterologous boosting responses involving CoronaVac for us to verify our findings. The significant increase in neutralising antibodies against Delta and Beta variants following boosting with BNT162b2 suggests that heterologous boosting with BNT162b2 is likely to be protective against these variants. However, an interesting finding was that individuals in the ChAdOx1-prime group had a blunted neutralising antibody response against the Delta and Beta variants following BBIBP-CorV or ChAdOx1 booster. This suggests that BBIBP-CorV or ChAdOx1 given as a booster to individuals who received ChAdOx1 as primary series may not offer additional protection against the Delta variant that is widely circulating globally. However, the number of participants for this analysis was small and larger studies are needed to verify this finding.

While neutralising antibodies are thought to be the primary mechanism of protection[7], virus-specific memory T cells are also important for protection. Only a third of ChAdOx1-prime and a quarter of CoronaVac-prime participants in our study had positive IGRA 8-12 weeks post primary series, suggesting that CoronaVac induce a poorer T cell memory response than ChAdOx1. Previous studies evaluating 2-dose ChAdOx1 primary series have reported the generation of robust T cell responses (measured by interferon gamma ELISPOT) 14 days following the first dose, with no significant increase in T cell responses following the second dose[20-21]. The discrepancy in T cell responses from our study could be due to waning immunity, population differences and the different assays used to measure interferon gamma response (Quantiferon vs inteferon gamma ELISPOT). Interestingly, boosting with standard or reduced dosage BNT162b2 induce robust T cell responses, whereas boosting with BBIBP or homologous boosting regimen of ChAdOx1 (third dose) appears to be a poor inducer of T cell responses. It is

important to note that inactivated vaccine (i.e. BBIBP) may have other antigens (i.e. M or N proteins) that induce T cell responses[22], whereas in our study, we only examined T cell responses to S protein, and thus may have underestimated the cellular responses. The low T cell boosting responses following homologous boosting regimen of ChAdOx1 is in line with the low neutralising antibody boosting responses against the Delta and Beta variants observed in this study. This could be explained by the anti-vector interference because of the primary vaccination, although more studies are needed to confirm this finding.

Our findings in both vaccine-prime groups suggested that less amount of antigen may be sufficient for boosting. We found that half-dose of 15 µg BNT162b2 was equally immunogenic as the standard dose of 30 µg, but with less reactogenicity. This is in concordance with a study on mRNA1273 vaccine where a booster dose of mRNA1273 vaccine at half the normal dosage (50 µg) was able to induce significantly higher neutralising antibodies than the level induced following primary series and against the VOCs[17]. Taken together, a lower mRNA vaccine dose may be an option for COVID-19 booster vaccination given the limited vaccine supply. However, the persistence of immunity and the efficacy following reduced dosages in booster vaccination remains to be determined.

There are some limitations in this study. First, our study was conducted in an open label manner due to the availability of each vaccine at a different timing. While this may lead to selection bias and subjective outcomes such as AEs, the demographic characteristics of the participants in the booster groups were very similar, suggesting that this is unlikely to influence our findings. Second, our sample size is small, particularly those who received BBIBP as booster, and therefore, the data need to be interpreted with caution. Furthermore, it is unclear if similar findings will be found if the duration between the last dose of primary series and the booster dose is >12 weeks (8-

12 weeks in this study). Last, the participants in this study were healthy adults therefore results may not be generalisable to other populations such as elderly or those with underlying diseases.

In conclusion, we found that a booster dose of BNT162b2 given to individuals previously vaccinated with CoronaVac or ChaAdOx1 primary series is the most immunogenic. Our study findings have important implications on the choice of booster dose following CoronaVac or ChAdOx1 primary series, and are most relevant for countries that have introduced these vaccines to date. Furthermore, our study indicates that reduced dosage of BNT162b2 may be used as a booster dose instead of the standard dosage. This will aid in improving global access to COVID-19 vaccines.

Methods

Study design and participants

This single-center prospective cohort study enrolled 352 healthy adults aged 18-60 years of age at Siriraj Hospital, a university-based referral center in Bangkok, Thailand, from March to September 2021. The eligible participants were those who have received either 2-dose 4 weeks apart of CoronaVac or 8-10 weeks apart of ChAdOx1 primary series vaccination in the period of 8-12 weeks prior the screening day. The exclusion criteria were history of SARS-CoV-2 infection; received prior administration of current prophylactic treatment or investigational agents against COVID-19 within 90 days; had an unstable underlying disease; history of vaccine anaphylaxis; being pregnant; immunocompromised or currently receiving immunosuppressive agents. The study procedures, risks, and benefits were explained to all participants before obtaining written informed consent. The study protocol was approved by the Siriraj Institutional Review Board

(COA no. Si 537/2021). The procedures in this study adhere to the tenets of the Declaration of Helsinki.

Study Procedures

The participants with prior 2-dose primary series of CoronaVac (CoronaVac-prime) or ChAdOx1 (ChAdOx1-prime) were openly assigned to receive one of the four intramuscular booster vaccinations: BBIBP-CorV (manufactured by Sinopharm), ChAdOx1, full dose (30 µg) BNT162b2 (manufactured by Pfizer), and half dose (15 µg) BNT162b2. Prior to enrollment, the potential participants who were interested to participate were provided an on-line questionnaire to select their first and second choice of booster vaccine which will be available at the time. The assigned booster vaccine was matched with the indicated pre-enrollment choice and the availability of the vaccine on the study day.

The participants were observed for at least 30 min following vaccination for any immediate adverse events (AE). Participants were instructed to record self-assessment signs or symptoms in an electronic diary (eDiary) for seven days after vaccination to track AE including solicited local and systemic adverse reactions. An AE in this study will be defined as any unfavorable or unexpected sign, symptom, or disease (including an unexpected finding in a laboratory evaluation) that occurs in any participant whether it is related to the vaccination product. Solicited local AE included pain, erythema, and swelling/induration at the injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Solicited systemic AE were headache, fatigue, myalgia, arthralgia, nausea, vomiting, rash, fever, and chills. The severity of solicited AE were graded using a numerical scale from 1 to 4 based on two guides; Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials from the

United States Food and Drug Administration (FDA), and in the Common Terminology Criteria for Adverse Events - Version 5.0 guide by the United States National Cancer Institute (NCI / NIH).

Blood samples were collected at baseline (pre-booster), and two weeks after booster vaccination (post-boost) to determine the level of antibody response (IgG) against receptor binding domain (RBD) of the SARS-CoV-2 S1 subunit spike protein (anti-RBD IgG) and 50% plaque reduction neutralisation test ($PRNT_{50}$) against Delta (B1.1617.2) and Beta (B.1.351) variants. The whole blood samples were collected for cellular immunity testing by the QuantiFERON SARS-CoV-2 interferon gamma release assay (IGRA) at baseline. The participants who had IGRA levels below the cut-off point were tested again at 2 weeks following the booster vaccination.

Chemiluminescent microparticle assay (CMIA) for anti-SARS-CoV-2 RBD IgG

The plasma samples were stored at -80ºC until testing in batch. The anti-RBD IgG was quantitatively measured by CMIA using the SARS-CoV-2 IgG II Quant (Abbott, List No. 06S60) on the ARCHITECT i System. This assay linearly measures the level of antibody between 21.0 - 40,000.0 arbitrary unit (AU)/mL, which was converted later to WHO international standard concentration as binding antibody unit per mL (BAU/mL) following the equation provided by the manufacturer (BAU/mL =0.142 x AU/mL). The level greater or equal to the cutoff value of 50 AU/mL or 7.1 BAU/mL was defined as seropositive. Seroconversion was determined as becoming seropositive in those who had seronegative at baseline or increase of 4-fold titres above the baseline seropositive levels.

50% plaque reduction neutralisation test ($PRNT_{50}$)

The standard live virus 50% plaque reduction neutralisation test ($PRNT_{50}$) against Delta variant (B.1.617.2) and Beta variant (B.1.351) were performed. Vero cells were seeded at 2x

10^5cells/well/ 3 ml and placed in 37°C, 5% CO_2 incubator for 1 day. Test sera were initially diluted at 1:10, 1:40, 1:160 and 1:640, respectively. SARS-CoV-2 virus was diluted in culture medium to yield 40-120 plaques/well in the virus control wells. Cell control wells, convalescent patient serum and normal human serum were also included as assay controls. The neutralisation was performed by mixing the equal volume of diluted serum and the optimal plaque numbers of SARS CoV-2 virus at 37˚C in water bath for 1 h. After removing the culture medium from Vero cell culture plates, 200 ul of the virus-serum antibody mixture were inoculated into monolayer cells and then rocked the culture plates every 15 min for 1 h. Three ml of overlay semisolid medium (containing 1% of carboxymethylcellulose, Sigma Aldrich, USA, with 1% of 10,000 units/ml penicillin, 10,000 ug/ml streptomycin (Sigma, USA), and 10% FBS) were replaced after removing excessive viruses. All plates were incubated at 37˚C, 5% CO_2 for 7 days. Cells were fixed with 10% (v/v) formaldehyde then stained with 0.5% crystal violet in PBS. The number of plaques formed was counted in triplicate wells and percentage of plaque reduction at 50% ($PRNT_{50}$) was calculated. The $PRNT_{50}$ titre of test sample is defined as the reciprocal of the highest test serum dilution for which the virus infectivity is reduced by 50% when compared with the average plaque counts of the virus control and was calculated by using a four-point linear regression method. Plaque counts for all serial dilutions of serum were scored to ensure that there was a dose response.

QuantiFERON SARS-CoV-2 interferon gamma release assay (IGRA)

SARS-CoV-2 specific T cell responses were assessed by whole blood IGRA using QIAGEN's proprietary mixes of SARS-CoV-2 S protein following manufacture's instruction. Briefly, whole blood samples were collected into the unstimulated tube as negative control and stimulated tubes containing SARS-CoV-2 S peptide designed for $CD4^+$ T cell (Ag.1), for $CD8^+$ T cells (Ag.2) and for mitogen as positive control. The specimen was incubated at 37°C for 16-24

hours and centrifuged to separate plasma. Interferon-gamma (IFN-ϒ) concentration in the plasma fraction was measured with an automated QuantiFERON SARS-CoV-2 ELISA instrument for research use only (RUO) and reported in International Units per mL (IU/mL)[23-24]. The cut-off for positivity was determined as the level above the mean plus three standard deviations of the negative control. Using 61 negative controls at the study site, the cut-offs for Ag1 and Ag2 were >0.12 IU/mL and >0.17 IU/mL, respectively. A positive response to either of the two peptides pools was considered positive.

Statistical Analysis

The AEs endpoints were presented as frequencies and Chi-square test was used to test for statistical difference. The immunological endpoints including anti-SARS-CoV-2 RBD IgG concentration and $PRNT_{50}$ titres at 2 weeks after booster vaccination (post-boost) were reported as geometric mean concentration (GMC) with 95% confidence interval (CI) if the data was positively skewed. The $PRNT_{50}$ titres below 10 were arbitrarily assigned a value of 5. We used the anti-RBD IgG GMC and the $PRNT_{50}$ geometric mean titres (GMT) at two weeks after the second dose of primary series vaccination (post-primary series) from our previous study as the references for comparison. The post-primary anti-RBD IgG GMC levels was 164.4 BAU/mL and 278.5 BAU/mL in 2-dose CoronaVac and ChAdOx1, respectively, while the respective $PRNT_{50}$ GMT was 21.2 and 69.7 for Delta variant and 10.2 and 43.5 for Beta variant[8]. Of note, 278 (79%) subjects in this study also participated in the primary series study with the data included. The geometric mean ratio (GMR) with 95% CI were analyzed between the post-boosting levels/titres and post-primary series levels/titres references. Unpaired t-test was used to compare GMC of the IgG concentrations between groups using GraphPad Prism 9 version 9.2.0 (283) (GraphPad Software,

CA, USA). A p-value less than 0.05 is considered statistically significance. All statistical analyses were conducted using STATA version 17 (Stata Corp, LP, College Station, TX, USA), SAS Studio.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgement

The authors gratefully acknowledge the Siriraj Institute of Clinical Research (SICRES) team, Abbott Laboratories Ltd. for technical supports and all health care workers who took part and enabled this study to be possible.

Author Contributions

N.A. and S.N. equally contributed to the research work. Conceptualization and Methodology, N.A., S.N., J.S., and K.C.; Formal analysis and data curation: N.A., J.S., S.N. R.T; Project administration, N.A, J.S., S.N.; Supervision, K.C.; Resources and Funding, K.C. All involved with investigation, and writing-review and editing.

Conflict of Interest Declaration

All authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and/or distribute the drugs, devices, or materials described in this report.

Funding Disclosure

This study was supported by the National Research Council of Thailand. The Abbott Laboratories Ltd. partially supported the reagents for the anti-SARS-CoV-2 RBD IgG in this study.

References

1. Tanriover, M. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *The Lancet* **398**, 213-222 (2021).

2. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* **397**, 99-111 (2021).

3. Jara, A. et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *New England Journal of Medicine* **385**, 875-884 (2021).

4. Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* **385**, 585-594 (2021).

5. Li, X. et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. *Emerging Microbes & Infections* **10**, 1751-1759 (2021).

6. Mallapaty, S. China's Covid vaccines have been crucial - now immunity is waning. *Nature News* (2021). Available at: https://www.nature.com/articles/d41586-021-02796-w. (Accessed: 21st October 2021)

7. Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers. Preprint at *medRxiv* https://doi:10.1101/2021.10.03.21264451 (2021).

8. Khoury, D. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine* **27**, 1205-1211 (2021).

9. Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. *The Lancet Regional Health - Europe* **10**, 100208 (2021).

10. Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *British Medical Journal* **373,** n1088 (2021).

11. AlQahtani, M. et al. Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain. Preprint at *Research Square* https://doi.org/10.21203/rs.3.rs-828021/v1 (2021).

12. Borobia, A. et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *The Lancet* **398**, 121-130 (2021).

13. Barros-Martins, J. et al. Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Preprint at *medRxiv* https://doi:10.1101/2021.06.01.21258172 (2021).

14. Gross, R. et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. Preprint at *medRxiv* https://doi:10.1101/2021.05.30.21257971 (2021).

15. Yorsaeng, R. et al. Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). Preprint at *medRxiv* https://doi:10.1101/2021.09.01.21262955 (2021).

16. Nordström, P., Ballin, M. & Nordström, A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. *The Lancet Regional Health - Europe* 100249 (2021).

17. Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nature Medicine* (2021).

18. Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *The Lancet Infectious Diseases* **21**, 939-949 (2021).

19. Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nature Medicine* **27**, 1525-1529 (2021).

20. Folegatti, P. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet* **396**, 467-478 (2020).

21. Ramasamy, M. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *The Lancet* **396**, 1979-1993 (2020).

22. Vályi-Nagy, I. et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. *GeroScience* **43**, 2321-2331 (2021).

23. Murugesan, K. et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response. *Clinical Infectious Diseases* **73**, e3130-e3132 (2020).

24. Martínez-Gallo, M. et al. Commercialized kit to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in Health Care Workers. Preprint at *medRxiv* https://doi:10.1101/2021.03.31.21254472 (2021).

Figure Legend

Fig. 1 Adverse events following four different booster vaccinations. The stacked bars showed the percentage of participants who reported mild and moderate adverse events after the booster vaccinations in the subjects who had received 2-dose CoronaVac-primary series (A) and ChAdOx1-primary series (B) vaccination. Chi-square was used for statistical analyses and the *p* values were shown on the graphs.

Fig. 2 Quantitation of anti-SARS-CoV-2 RBD IgG after booster vaccination. The scatter dot plot demonstrates the anti-SARS-CoV-2 RBD IgG concentration before and 2 weeks after different booster vaccination in the plasma of study subjects who had received 2-doses CoronaVac primary series **(A)** or ChAdOx1-primary series **(B)** 8-12 weeks prior. The numbers in the graph represent geometric mean and the error bars represent 95% confidence interval. The number of tested samples were indicated for each type for booster vaccine. The upper dotted line represents the geometric mean concentration (GMC) of anti-SARS-CoV-2 RBD IgG at 2 weeks after the second dose of the 2-dose primary series 4 weeks apart of CornaVac (A) and 8 weeks apart of ChAdOx1 (B) from reference Angkasekwinai N, et al. *medRxiv* preprint doi: https://doi.org/10.1101/2021.10.03.21264451, and the lower dot line represents the cut-off level for seropositivity. Indicated *p* values were for the unpair t test comparison between different types of booster vaccine and the pair t test comparison between before and after boost. The value of 11,360 BAU/mL was used for any samples that were reported> 11,360 BAU/mL by the machine. The scatter dot plot demonstrates the level of anti-SARS-CoV-2 RBD IgG at 2 weeks after various booster vaccination in the plasma of study subjects who had completed 2-doses of CoronaVac primary series (blue) or ChAdOx1 primary series (red) **(C)**. The numbers in the

graph represent GMC and the error bars represent 95% confidence interval. The number of tested samples were indicated for each type for booster vaccine. Unpair t test was used to compare between each group with indicated *p* value.

Fig. 3 Plaque reduction neutralisation test ($PRNT_{50}$) titres for SARS-CoV-2 delta and beta variants after different booster vaccines. Scatter dot plots demonstrate $PRNT_{50}$ titre against the **(A)** delta or **(B)** beta strain at 2 weeks after different booster vaccines in the study subjects who had completed two doses of Coronavac or ChAdOx1 for 8-12 weeks. The $PRNT_{50}$ titre of 1:5 was used for all that were below the detectable level (< 1:10). The numbers in the graph represent geometric mean titre (GMT) and the error bars represent 95% confidence interval (CI). The upper dotted line represents the geometric mean values of anti-SARS-CoV-2 RBD IgG at 2 weeks after the second dose of the 2-dose primary series 4 weeks apart of CornaVac (A) and 8 weeks apart of ChAdOx1 (B) from reference Angkasekwinai N, et al. *medRxiv* preprint doi: https://doi.org/10.1101/2021.10.03.21264451; and the lower dot line represents the cut-off level for seropositivity. Unpaired t tests were used for statistical analyses and the *p* values were indicated. **(C)** comparison of the plaque reduction neutralisation test ($PRNT_{50}$) titres for the SARS-CoV-2 delta and beta variants after different booster vaccine in among each primary series. Aligned dot plots show the $PRNT_{50}$ titre against the delta (teal) or beta (pink) variant in the plasma of study subjects who had completed two doses of CoronaVac or ChAdOx1 at 2 weeks after booster with BBIBP-CorV, ChAdOX1, 30 μg. BNT162b2 and 15 μg. BNT162b2. The $PRNT_{50}$ titre of 1:5 was used for all that were below the detectable level (< 1:10). Ratio paired t test was used for statistical analyses.

Fig. 4 Correlation between the level of anti-SARS-CoV-2 RBD IgG and plaque reduction neutralisation test ($PRNT_{50}$) titres for the SARS-CoV-2 delta and beta variants. Dot plots show the correlation between the level of anti-SARS-CoV-2 RBD IgG and $PRNT_{50}$ titre against the **(A, B)** delta or **(C, D)** beta variant in the plasma of study subjects who had completed two doses of CoronaVac or ChAdOx1 at 2 weeks after booster with BBIBP-CorV (green), ChAdOX1 (red), 30 μg. BNT162b2 (orange) and 15 μg. BNT162b2 (yellow). The $PRNT_{50}$ titre of 1:5 was used for all that were below the detectable level (< 1:10). Pearson's correlation coefficient (r) with *p* value for each booster vaccine was indicated.

Supplementary Fig S1. Comparison of the cellular immune responses after different booster vaccine among each primary series by interferon-gamma (IFNγ) releasing assay (IGRA). Scatter dot plots show the level of IFNγ production in the blood after being stimulated with either Ag1 or Ag2 before booster vaccination **(A)**. The blood samples were collected at 8-12 weeks after two doses of CoronaVac or ChAdOx1. Mann-Whitney test was used for statistical analyses. **Comparison of the cellular immune responses after different booster vaccine among each primary series by IGRA in those who were seronegative before booster vaccination.** Aligned dot plots show the level of IFNγ production in the blood after being stimulated with either **(B)** Ag1 or **(C)** Ag2 comparing between before (teal) and 2 weeks after (pink) booster with BBIBP-CorV, ChAdOX1, 30 μg BNT162b2 and 15 μg BNT162b2. Wilcoxon matched-pairs signed rank test was used for statistical analyses. Median and interquartile range (IQR) of each group are indicated. Ag.1 was derived from SARS-CoV-2 S peptide for CD4+ T cell stimulation and Ag.2 was for CD8+ T cells stimulation. Interferon-gamma (IFN-ϒ) concentration in the plasma fraction was measured with an automated

QuantiFERON SARS-CoV-2 ELISA instrument for research use only (RUO) and reported in international Units per mL (IU/mL).

Table 1 Characteristics of 352 participants classified by primary series vaccination.

Demographics	Type of booster vaccinations				
CoronaVac-prime (n=179)					
	BBIBP-CorV n=14	ChAdOx1 n=65	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value
Age (years), median (IQR)	31 (27, 41.5)	36.6 (29.5, 44)	32 (28, 41.8)	40 (31.5, 45.3)	0.018
Female, n (%)	12 (85.7)	51 (78.5)	40 (80.0)	33 (66.0)	0.249
BMI (kg/m^2), median (IQR)	25.2 (21.1, 31.6)	23.4 (20.9, 27.1)	22.1 (19.5, 25.5)	23.9 (20.9, 26.0)	0.325
Anti-RBD IgG GMC at baseline (95%CI)	34.32 (22.33, 52.77)	38.18 (31.21, 46.71)	33.31 (26.72, 41.53)	37.67 (31.65, 44.84)	0.7616
Anti-RBD IgG GMC after boosting (95%CI)	154.6 (92.11, 259.47)	1358.0 (1141.84, 1615.07)	5152.2 (4491.65, 5909.83)	3981.1 (3397.15, 4665.42)	<0.0001
Baseline SARS-CoV-2 IGRA positive, n (%)	5 (35.7)	12 (18.5)	16 (32)	12 (24)	0.301

Post-boosting IGRA positive among baseline negative participants, n (%)	1/9 (11.1)	26/53 (49.1)	28/34 (82.4)	30/38 (79.0)	<0.0001
ChAdOx1-prime (n=173)					
	BBIBP-CorV n=23	ChAdOx1 n=50	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value
Age (years), median (IQR)	51 (42, 59)	45.5 (36, 57)	34 (30, 43)	41.5 (34, 49.5)	0.001
Female, n (%)	21 (91.3)	47 (94.0)	37 (74.0)	44 (88.0)	0.001
BMI (kg/m^2), median (IQR)	24.8 (22.4, 27.6)	23.8 (21.3, 26.7)	21.4 (19.3, 24.7)	23.3 (20.4, 26.5)	0.001
Anti-RBD IgG at baseline (95%CI)	106.6 (70.89, 160.29)	105.7 (80.97, 137.97)	95.98 (75.84, 121.45)	90.11 (73.62, 110.30)	0.7661
Anti-RBD IgG GMC after boosting (95%CI)	128.1 (93.52, 175.37)	246.4 (199.59, 304.20)	2363.8 (2005.58, 2786.06)	1961.9 (1624.61, 2369.10)	<0.0001
Baseline SARS-CoV-2 IGRA positive, n (%)	13 (56.5)	26 (52.0)	9 (18.0)	14 (28.0)	<0.0001

Post-boosting IGRA positive among baseline negative participants, n (%)	0/10	0/24	31/41 (75.6)	24/26 (66.7)	<0.0001

GMC: geometric mean concentration; IGRA: QuantiFERON SARS-CoV-2 interferon gamma release assay

Table 2 The 50% plaque reduction neutralization ($PRNT_{50}$) geometric mean antibody titers (GMT) and the geometric mean ratio (GMR) between post-boosting and post-primary series*.

$PRNT_{50}$ GMT	Type of booster vaccinations				
CoronaVac-prime (n=104)					
	BBIBP-CorV n=14	ChAdOx1 n=30	30 µg BNT162b2 n=30	15 µg BNT162b2 n=30	*p*-value
GMT (95% CI) against Delta variant	61.3 (35.07, 107.02)	271.2 (222.54, 330.49)	411.1 (311.71,542.16)	499.12 (418.54, 595.21)	<0.0001
GMR (95% CI) between post-boosting and post-primary series* against Delta variant	2.89 (1.52, 5.50)	12.79 (9.06, 18.06)	19.39 (13.04, 28.84)	23.54 (16.89, 32.82)	<0.0001
GMT (95% CI) against Beta variant	37.2 (18.00, 76.91)	170.5 (124.65, 233.13)	306.7 (221.44, 424.71)	322.8 (239.34, 435.25)	<0.0001
GMR (95% CI) between post-boosting and post-primary series* against Beta variant	3.65 (1.65, 8.08)	16.72 (11.11, 25.15)	30.07 (19.79, 45.69)	31.65 (21.27, 47.09)	<0.0001
ChAdOx1-prime					

	BBIBP-CorV n=22	ChAdOx1 n=30	30 µg BNT162b2 n=30	15 µg BNT162b2 n=30	*p*-value
GMT (95% CI) against Delta variant	49.0 (37.56, 64.05)	69.1 (50.14, 95.14)	470.1 (395.49, 558.89)	358.4 (276.13, 465.26)	<0.0001
GMR between post-boosting and post-primary series* (95% CI) against Delta variant	0.70 (0.44, 1.12)	0.99 (0.60, 1.63)	6.74 (4.45, 10.23)	5.14 (3.24, 8.16)	<0.0001
GMT (95% CI) against Beta variant	28.1 (18.08, 43.53)	38.2 (26.06, 56.05)	292.9 (233.73, 367.17)	250.0 (182.95, 341.51)	<0.0001
GMR (95% CI) between post-boosting and post-primary series* against Beta variant	0.65 (0.36, 1.15)	0.88 (0.52, 1.49)	6.73 (4.42, 10.26)	5.75 (3.57, 9.24)	<0.0001

*The post primary series GMC was derived from the study in the same setting as the current study (Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers. Preprint at *medRxiv* https://doi:10.1101/2021.10.03.21264451 (2021)). The post primary series GMT (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac, 4 weeks apart, were 21.2 (16.07, 27.87) and 10.2 (7.92, 13.12) against Delta and Beta variants, respectively; and after 2-dose

homologous ChAdOx1,10 weeks apart, were 69.7 (48.08, 101.00) and 43.5 (30.73, 61.72) against Delta and Beta variants, respectively.

Supplementary Table 1 Adverse events of following booster vaccination.

Adverse events (AEs)	BBIBP-CorV	ChAdOx1	30 µg BNT162b2	15 µg BNT162b2	p-value
CoronaVac-prime (n=179)	n=14	n=65	n=50	n=50	
Overall AEs (%)	10 (71.43)	64 (98.46)	46 (92.0)	40 (80.0)	0.002
Injection site reaction (%)	9 (64.29)	62 (95.38)	46 (92.00)	36 (72.00)	<0.001
Fatigue (%)	2 (14.29)	46 (70.77)	26 (52.0)	10 (20.00)	<0.001
Headache (%)	1 (7.14)	12 (18.46)	25 (50.0)	18 (36.0)	<0.001
Myalgia (%)	6 (42.86)	54 (83.08)	2 (4.0)	1 (2.0)	<0.001
Malaise (%)	0	1 (1.54)	31 (62.0)	20 (40.0)	<0.001
Nausea (%)	2 (14.29)	20 (30.77)	7 (14.0)	5 (10.0)	0.119
Diarrhea (%)	1 (7.14)	12 (18.46)	3 (6.0)	6 (12.0)	0.284
Fever (%)	1 (7.14)	25 (38.46)	4 (8.0)	1 (2.0)	<0.001
Rash (%)	2 (14.29)	9 (13.85)	7 (14.0)	2 (4.0)	0.341
Somnolence (%)	0	0	2 (4.0)	2 (4.0)	0.357
Flu-like symptoms (%)	0	4 (6.15)	1 (2.0)	1 (2.0)	0.453
Arthralgia (%)	0	2 (3.08)	1 (2.0)	1 (2.0)	0.906
Dizziness (%)	0	1 (1.54)	1 (2.0)	0	0.758
Paresthesia (%)	2 (14.29)	1 (1.54)	1 (2.0)	0	0.014
Vomiting (%)	0	4 (6.15)	0	1 (2.0)	0.199
ChAdOx1-prime (n=173)	n=23	n=50	n=50	n=50	

Overall AEs (%)	14 (60.87)	36 (72.0)	49 (958.0)	44 (89.0)	<0.001
Injection site reaction (%)	9 (39.13)	28 (56.0)	47 (94.00)	44 (88.00)	<0.001
Fatigue (%)	3 (13.04)	18 (36.0)	34 (68.0)	20 (40.00)	<0.001
Headache (%)	6 (26.09)	15 (30.0)	28 (56.0)	28 (56.0)	0.024
Myalgia (%)	6 (42.86)	54 (83.08)	2 (4.0)	1 (2.0)	<0.001
Malaise (%)	7 (30.43)	21 (42.0)	34 (68.0)	37 (74)	0.001
Nausea (%)	1 (4.35)	20 (30.77)	7 (14.0)	5 (10.0)	0.102
Diarrhea (%)	1 (4.35)	5 (10.0)	8 (16.0)	6 (10.0)	0.834
Fever (%)	1 (4.35)	2 (4.0)	4 (8.0)	1 (2.0)	0.240
Rash (%)	0	1 (2.0)	1 (2.0)	0	0.688
Somnolence (%)	0	1 (2.0)	2 (4.0)	0	0.421
Flu like symptoms (%)	0	1 (2.0)	2 (4.0)	2 (4.0)	0.738
Arthralgia (%)	0	0	0	1 (2.0)	0.480
Dizziness (%)	2 (8.70)	1 (2.0)	0	0	0.118
Paresthesia (%)	0	0	0	0	-
Vomiting (%)	0	3 (6.0)	0	0	0.057

Supplementary Table 2 The geometric mean anti-RBD IgG concentration (GMC) and the geometric mean ratio (GMR) between post boosting and baseline or post primary series*.

Anti-RBD IgG antibody concentration (GMC)	Type of booster vaccinations				
CoronaVac-prime (n=179)					
	BBIBP-CorV n=14	ChAdOx1 n=65	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value between groups
GMC at baseline (95%CI)	34.32 (22.33, 52.77)	38.18 (31.21, 46.71)	33.31 (26.72, 41.53)	37.67 (31.65, 44.84)	0.7616
GMC after boosting (95%CI)	154.6 (92.11, 259.47)	1358.0 (1141.84, 1615.07)	5152.2 (4491.65, 5909.83)	3981.1 (3397.15, 4665.42)	<0.0001
GMR between post-boosting and baseline (95% CI)	4.5 (2.98, 6.80)	35.6 (29.18, 43.34)	154.7 (124.30, 192.50)	105.7 (90.31, 123.68)	<0.0001
GMR between post-boosting and post primary series of CoronaVac*	0.94 (0.53, 1.67)	8.26 (6.29, 10.85)	31.34 (24.37, 40.30)	24.22 (18.60, 31.54)	<0.0001
ChAdOx1-prime (n=173)					

	BBIBP-CorV n=23	ChAdOx1 n=50	30 µg BNT162b2 n=49	15 µg BNT162b2 n=50	*p*-value between groups
Geometric mean level at baseline (95%CI)	106.6 (70.89, 160.29)	105.7 (80.97, 137.97)	95.98 (75.84, 121.45)	90.11 (73.62, 110.30)	0.7661
Geometric mean level after boosting (95%CI)	128.1 (93.52, 175.37)	246.4 (199.59, 304.20)	2363.8 (2005.58, 2786.06)	1961.9 (1624.61, 2369.10)	<0.0001
GMR between post-boosting and baseline (95% CI)	1.2 (1.01, 1.43)	2.3 (1.92, 2.83)	25.1 (20.30, 31.01)	21.8 (18.28, 25.92)	<0.0001
GMR between post-boosting and post primary series of ChAdOx1*	0.46 (0.28, 0.65)	0.88 (0.58, 1.13)	8.49 (5.71, 10.44)	7.04 (4.69, 8.84)	<0.0001

*The post primary series GMC was derived from the study in the same setting as the current study (Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers. Preprint at *medRxiv* https://doi:10.1101/2021.10.03.21264451 (2021)). The post primary series GMC (95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac, 4 weeks apart, was 164.4 (133.55, 202.43); and after 2-dose homologous ChAdOx1,10 weeks apart, was 278.5 (195.66,396.33).


CoronaVac primary series
ChAdOx1 primary series
Mild (Grade 1)
Moderate (Grade 2)
Overall adverse events
Injection site reaction
Myalgia
Fatigue
Headache
Nausea
Diarrhea
Fever
BBIBP-CorV
ChAdOx1
BNT162b2 [30 µg]
BNT162b2 [15 µg]
0
25
50
75
100
Percent (%)


A
BAU/mL
****
p < 0.0001
(Paired t test)
****
p < 0.0001
****
p < 0.0001
*
p = 0.0152
(Unpaired t test)
10,000
1,000
100
10
1
154.6
34.32
1,358
38.18
5,152
33.31
3,981
37.67
(164.4 BAU/mL)
GM at 2 weeks post 2nd dose
cut-off for positive 7.1 BAU/mL
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)
(n = 14)
(n = 65)
(n = 50)
(n = 49)
8-12 weeks after 2nd dose
2 weeks after booster
B
BAU/mL
*
p = 0.0386
(Paired t test)
****
p < 0.0001
(Paired t test)
***
p = 0.0007
****
p < 0.0001
ns
p = 0.1381
(Unpaired t test)
128.1
106.6
246.4
105.7
2,364
94.23
1,962
90.11
(278.5 BAU/mL)
GM at 2 weeks post 2nd dose
cut-off for positive 7.1 BAU/mL
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)
(n = 23)
(n = 50)
(n = 50)
(n = 49)
8-12 weeks after 2nd dose
2 weeks after booster
C
BAU/mL
ns
p = 0.4890
****
p < 0.0001
****
p < 0.0001
****
p < 0.0001
154.6
128.1
1,358
246.4
5,152
2,364
3,981
1,962
GM at 2 weeks post 2nd dose of ChAdOx1 (278.5 BAU/mL)
GM at 2 weeks post 2nd dose of CoronaVac (164.4 BAU/mL)
CoronaVac primary series
ChAdOx1 primary series
cut-off for positive 7.1 BAU/mL
(n = 14)
(n = 23)
(n = 65)
(n = 50)
(n = 50)
(n = 50)
(n = 50)
(n = 49)
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)


A
PRNT50 titer
CoronaVac primary series
ChAdOx1 primary series
****
p < 0.0001
*
p = 0.0152
ns
p = 0.2312
ns
p = 0.1152
****
p < 0.0001
ns
p = 0.0815
GMT at 2 weeks post 2nd dose of ChAdOx1 (69.69)
GMT at 2 weeks post 2nd dose of CoronaVac (21.19)
detectable level = 10
61.27
(35.07 - 107.02)
271.19
(222.54 - 330.49)
411.09
(311.71 - 542.16)
499.12
(416.54 - 595.21)
49.05
(37.56 - 64.05)
69.07
(50.15 - 95.14)
470.14
(395.49 - 558.89)
358.43
(276.13 - 465.26)
GMT
(95% CI)
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)
(n = 14)
(n = 30)
(n = 30)
(n = 30)
(n = 22)
(n = 30)
(n = 30)
(n = 30)


B
PRNT50 titer
CoronaVac primary series
ChAdOx1 primary series
****
p < 0.0001
*
p = 0.0101
ns
p = 0.6139
ns
p = 0.2812
****
p < 0.0001
ns
p = 0.4029
GMT at 2 weeks post 2nd dose of ChAdOx1 (43.55)
GMT at 2 weeks post 2nd dose of CoronaVac (10.16)
detectable level = 10
37.21
(18.00 - 76.91)
170.47
(124.65 - 233.13)
306.67
(221.44 - 424.71)
322.76
(238.34 - 435.25)
28.06
(16.08 - 43.53)
38.22
(26.06 - 56.05)
292.95
(233.73 - 367.17)
249.96
(162.95 - 341.51)
GMT
(95% CI)
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)
(n = 14)
(n = 30)
(n = 30)
(n = 30)
(n = 22)
(n = 30)
(n = 30)
(n = 30)


C
PRNT50 titer
CoronaVac primary series
ChAdOx1 primary series
p = 0.0033
**
p = 0.0002
***
p = 0.0014
**
p < 0.0001
****
p = 0.0028
**
p < 0.0001
****
p < 0.0001
****
p < 0.0001
****
detectable level = 10
Delta
Beta
(61.27)
(37.21)
(271.19)
(170.47)
(411.09)
(306.67)
(499.12)
(322.76)
(49.05)
(28.06)
(69.07)
(38.22)
(470.14)
(292.95)
(358.43)
(249.96)
(GMT)
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)
(n = 14)
(n = 30)
(n = 30)
(n = 30)
(n = 22)
(n = 30)
(n = 30)
(n = 30)


A
PRNT50 titer
BBIBP-CorV
ChAdOx1
BNT162b2 (30 μg)
BNT162b2 (15 μg)
r = 0.57 (p = 0.0010)
r = 0.70 (p < 0.0001)
r = 0.58 (p = 0.0007)
r = 0.84 (p = 0.0002)
detectable level = 10
CoronaVac primary series
BAU/mL
anti-SARS-CoV-2 RBD IgG
B
PRNT50 titer
BBIBP-CorV
ChAdOx1
BNT162b2 (30 μg)
BNT162b2 (15 μg)
r = 0.87 (p < 0.0001)
r = 0.77 (p < 0.0001)
r = 0.68 (p < 0.0001)
r = 0.83 (p < 0.0001)
detectable level = 10
ChAdOX1 primary series
BAU/mL
anti-SARS-CoV-2 RBD IgG
C
PRNT50 titer
BBIBP-CorV
ChAdOx1
BNT162b2 (30 μg)
BNT162b2 (15 μg)
r = 0.62 (p = 0.0003)
r = 0.67 (p = 0.0001)
r = 0.49 (p = 0.0059)
r = 0.80 (p = 0.0006)
detectable level = 10
CoronaVac primary series
BAU/mL
anti-SARS-CoV-2 RBD IgG
D
PRNT50 titer
BBIBP-CorV
ChAdOx1
BNT162b2 (30 μg)
BNT162b2 (15 μg)
r = 0.85 (p < 0.0001)
r = 0.72 (p < 0.0001)
r = 0.72 (p < 0.0001)
r = 0.83 (p = 0.0015)
detectable level = 10
ChAdOX1 primary series
BAU/mL
anti-SARS-CoV-2 RBD IgG


Ag-NIl (IU/mL)
ns
p = 0.0899
p = 0.0109
p = 0.0041
p = 0.0005
0.04
0.06
0.05
0.10
(0.01 - 0.08)
(0.02 - 0.14)
(0.01 - 0.14)
(0.025 - 0.23)
IQR
Ag1
Ag2
Ag1
Ag2
CoronaVac
(n = 179)
ChAdOx1
(n = 173)

A


Ag1-NIl (IU/mL)
Before booster
2 weeks after booster
(Median)
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)
(n = 9)
(n = 55)
(n = 34)
(n = 38)
(n = 12)
(n = 28)
(n = 40)
(n = 36)
CoronaVac primary series
ChAdOx1 primary series

B


Ag2-NIl (IU/mL)
Before booster
2 weeks after booster
(Median)
BBIBP-CorV
ChAdOx1
BNT162b2 (30 µg)
BNT162b2 (15 µg)
(n = 9)
(n = 55)
(n = 34)
(n = 38)
(n = 12)
(n = 28)
(n = 40)
(n = 36)
CoronaVac primary series
ChAdOx1 primary series

C